No Data
No Data
Oncternal Therapeutics | 10-Q: Quarterly report
Express News | Oncternal Therapeutics- Cash, Cash Equivalents and Short-Term Investments Totaled $27.0 Mln as of March 31, 2024; Cash Runway Projected Into Q1 2025
Oncternal Therapeutics 1Q Rev $569,000 >ONCT
Oncternal Therapeutics 1Q Rev $569,000 >ONCT
Express News | Oncternal Therapeutics Q1 Operating Expenses USD 9.348 Million
Express News | Oncternal Therapeutics Q1 Income From Operations USD -8.779 Million
Express News | Oncternal Therapeutics Q1 Basic EPS USD -2.83